Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free TCRT Stock Alerts

Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$1.90 -0.03 (-1.55%)
Closing price 07/28/2026 03:59 PM Eastern
Extended Trading
$1.93 +0.03 (+1.58%)
As of 07/28/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TCRT vs. DTIL, VYGR, MDWD, IVVD, and EQ

Should you buy Alaunos Therapeutics stock or one of its competitors? MarketBeat compares Alaunos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alaunos Therapeutics include Precision BioSciences (DTIL), Voyager Therapeutics (VYGR), MediWound (MDWD), Invivyd (IVVD), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.

How does Alaunos Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Alaunos Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$34.26M5.40-$45.72M-$3.67N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

Precision BioSciences currently has a consensus target price of $32.25, indicating a potential upside of 349.79%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Precision BioSciences is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Precision BioSciences-96.73% -85.37% -37.34%
Alaunos Therapeutics N/A -165.94%-123.50%

In the previous week, Precision BioSciences had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Precision BioSciences' score of 1.38 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Precision BioSciences Positive
Alaunos Therapeutics Very Positive

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Precision BioSciences has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the broader market.

Summary

Precision BioSciences beats Alaunos Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Voyager Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alaunos Therapeutics has a beta of -1.02, suggesting that its share price is 202% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, Voyager Therapeutics had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Voyager Therapeutics and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Voyager Therapeutics' score of 0.94 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Alaunos Therapeutics Very Positive
Voyager Therapeutics Positive

Alaunos Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -165.94% -123.50%
Voyager Therapeutics -319.61%-55.97%-43.12%

Alaunos Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A
Voyager Therapeutics$40.37M4.55-$119.72M-$1.97N/A

Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 442.76%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Voyager Therapeutics beats Alaunos Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Alaunos Therapeutics compare to MediWound?

Alaunos Therapeutics (NASDAQ:TCRT) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

MediWound has a consensus price target of $34.00, suggesting a potential upside of 132.56%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MediWound
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Alaunos Therapeutics has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A
MediWound$14.48M12.98-$23.88M-$2.26N/A

In the previous week, MediWound had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for MediWound and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 equaled MediWound'saverage media sentiment score.

Company Overall Sentiment
Alaunos Therapeutics Very Positive
MediWound Very Positive

Alaunos Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -165.94% -123.50%
MediWound -180.30%-67.22%-31.87%

Alaunos Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MediWound beats Alaunos Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Invivyd?

Alaunos Therapeutics (NASDAQ:TCRT) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alaunos Therapeutics has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A
Invivyd$53.43M3.27-$52.49M-$0.31N/A

Invivyd has a consensus price target of $8.00, indicating a potential upside of 1,248.39%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Invivyd
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Invivyd had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Invivyd's score of 0.94 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Alaunos Therapeutics Very Positive
Invivyd Positive

Alaunos Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Alaunos Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -165.94% -123.50%
Invivyd -138.90%-53.48%-41.56%

Summary

Invivyd beats Alaunos Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Equillium?

Equillium (NASDAQ:EQ) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

27.1% of Equillium shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alaunos Therapeutics has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Equillium$41.10M3.57-$22.40M-$0.32N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

In the previous week, Equillium had 6 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 7 mentions for Equillium and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Equillium's score of 1.29 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Equillium Positive
Alaunos Therapeutics Very Positive

Equillium's return on equity of -61.43% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
EquilliumN/A -61.43% -53.72%
Alaunos Therapeutics N/A -165.94%-123.50%

Equillium presently has a consensus price target of $7.57, suggesting a potential upside of 226.35%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts clearly believe Equillium is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Equillium
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.82
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Equillium has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market.

Summary

Equillium beats Alaunos Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

Export
MetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.13M$3.05B$7.08B$12.19B
Dividend YieldN/A2.06%2.66%8.55%
P/E Ratio-0.8920.4727.2823.75
Price / SalesN/A799.56578.34109.45
Price / CashN/A27.2749.6059.05
Price / Book2.044.0910.136.06
Net Income-$4.18M$67.27M$3.60B$336.44M
7 Day Performance-2.56%-3.34%-0.95%-1.50%
1 Month Performance-19.83%-7.64%-3.60%-4.62%
1 Year Performance-31.41%12.49%20.53%15.02%

Alaunos Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
1.072 of 5 stars		$1.90
-1.6%		N/A-36.7%$47.13MN/AN/A40
DTIL
Precision BioSciences
3.0233 of 5 stars		$7.33
+0.1%		$32.25
+340.0%		+40.6%$188.87M$34.26MN/A200
VYGR
Voyager Therapeutics
2.6398 of 5 stars		$3.09
-0.3%		$16.50
+434.0%		-7.0%$187.31M$40.37MN/A100
MDWD
MediWound
3.6816 of 5 stars		$14.27
-1.0%		$34.00
+138.3%		-26.6%$185.33M$16.96MN/A80
IVVD
Invivyd
2.6716 of 5 stars		$0.61
-1.8%		$8.00
+1,213.2%		-29.1%$182.69M$53.43MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 7/29/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel